#United States #San Antonio #Frost & Sullivan #WuXi AppTec #CRDMO

WuXi AppTec Secures Global Recognition in CRDMO Excellence

On October 19, 2026, WuXi AppTec celebrated a notable achievement when Frost & Sullivan awarded it the prestigious title of Global Company of the Year in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector. This honor reflects WuXi AppTec's unwavering commitment to innovation, operational excellence, and impactful customer relationships in a rapidly changing global landscape.

Frost & Sullivan's evaluation process, renowned for its rigorous benchmarking standards, focuses on two main dimensions: strategy effectiveness and execution. WuXi AppTec stood out by demonstrating a robust CRDMO model that integrates extensive capabilities with global manufacturing capacity. The company's commitment to quality management throughout the drug development cycle, supported by a strategic network across Asia, Europe, and North America, further enhances its operational resilience and flexibility.

Unmesh Lal, Vice President of Healthcare and Life Sciences at Frost & Sullivan, commented on WuXi AppTec’s achievement. He emphasized, "WuXi AppTec distinguishes itself through its strong focus on evolving customer needs. Its commitment to customer success reinforces its position as a trusted partner to biopharmaceutical innovators worldwide." This sentiment encapsulates the essence of WuXi AppTec's operational ethos, emphasizing its alignment with the evolving challenges faced by its partners in the biopharmaceutical industry.

In response to the recognition, Dr. Ge Li, Chairman and CEO of WuXi AppTec, expressed gratitude. He remarked, "We are honored that Frost & Sullivan has once again recognized what our teams deliver every day for customers. As a dedicated enabler of the pharmaceutical industry, we will remain committed to our CRDMO strategy, helping customers bring life-changing therapies to market faster and benefit patients around the world." This affirmation of their purpose illustrates WuXi AppTec's dedication to facilitating innovations that directly impact patient care across the globe.

At the core of WuXi AppTec’s growth strategy is a robust commitment to innovation. The company continues to invest in enhancing its development and manufacturing capabilities, particularly in advanced technologies and emerging therapeutic modalities. This includes areas such as oligonucleotides, peptides, and related conjugated medicines. These strategic investments are designed not only to optimize lead candidate selection but also to accelerate the efficiency of the development process, thus shortening the time required to bring new therapies to market.

In terms of operational excellence, WuXi AppTec emphasizes the significance of quality and regulatory compliance. In just the year 2025, the company successfully navigated 741 regulatory inspections and customer audits, achieving zero critical findings—a testament to its rigorous quality assurance protocols. The implementation of a One Global Quality System supports consistent governance and best practices across all operational locations. Furthermore, WuXi AppTec's integrated project management capabilities empower teams to respond effectively to complex technical and regulatory challenges.

Frost & Sullivan presents its Global Company of the Year Recognition to organizations that exemplify exceptional strategy development and execution. This accolade is awarded to companies that achieve measurable improvements in market standing, customer value, and competitive ability. The recognition not only honors WuXi AppTec’s strategic foresight but also highlights the company’s instrumental role in shaping the future of the CRDMO sector through its commitment to both innovation and excellence.

The Frost & Sullivan Best Practices Recognition program honors organizations globally for excellence across various sectors, showcasing exceptional achievements and consistent leadership in several dimensions, including technological innovation and customer experience. Each recognition stems from an extensive analytical process, which incorporates detailed interviews, in-depth analyses, and thorough research aimed at identifying the leaders who drive transformative growth and set new standards within their industries.

In summary, WuXi AppTec’s recognition as the 2026 Global Company of the Year underscores its pivotal role in the pharmaceutical and life sciences industry. Through its unwavering focus on customer success, commitment to quality, and dedication to advancing healthcare innovations, WuXi AppTec continues to foster significant contributions to the global biopharmaceutical landscape.

As the company moves forward, its vision remains clear: to enable every drug to be developed and every disease to be treated, one collaboration at a time. For more information about WuXi AppTec and its services, visit www.wuxiapptec.com.